Red Light Holland Corp. (CSE: TRIP) said on July 16, 2026 that its subsidiary Filament Health Corp. has completed a shipment of PEX010, a botanical psilocybin drug candidate, into the European Union. According to the release, the batch was released by Filament's European Qualified Person — the individual legally responsible under EU rules for certifying that a medicinal product batch may be released for use.
The material is destined for investigator-led studies, including work associated with Nantes University Hospital and Region Stockholm in collaboration with Karolinska Institutet. Red Light Holland states that each of those studies is sponsored and run independently of Filament, and that Filament's role is limited to supplying the drug.
That distinction matters for how a reader should size the announcement. The company disclosed no quantity shipped, no contract value, and no indication of whether the supply is sold, provided at cost or donated. Nothing in the release identifies revenue attached to the shipment, and no financial terms of any kind are given.
Red Light Holland describes PEX010 as supporting more than 80 academic and philanthropic research studies worldwide, and positions Filament as a supplier of pharmaceutical-grade natural psilocybin. Those are the company's own characterisations rather than independently verified figures.
The Filament acquisition, which Red Light Holland completed on April 30, 2026, brought with it PEX010 and a portfolio the company describes as 76 issued patents across 13 patent families. The consideration paid and any share issuance connected to that transaction are not restated in this release, so the effect on share count and cash is not visible from the document.
Chief executive Todd Shapiro, who holds the CEO and director roles at both Red Light Holland and Filament, said the shipments "reflect growing demand for pharmaceutical grade, naturally derived psilocybin."
Alongside its psychedelic drug development activity, Red Light Holland operates commercial businesses in Europe and North America, including psilocybin truffle sales in the Netherlands and mushroom home-grow kits sold through business-to-business and direct-to-consumer channels.
One administrative detail is worth flagging: the release names Rhelion Life Sciences Corp. as its source, without explanation in the document itself.
In substance, this is an operational update rather than a financial one. It confirms that Filament's cross-border supply and quality systems produced a released batch for EU-based academic research. It does not disclose volumes, pricing, booked revenue, cash on hand or burn rate — the figures that would show whether the supply business is material to the company's results.
Source: Newsfile
This article is journalism, not investment advice. It is not an offer or solicitation to buy or sell any security. Micro-cap and penny stocks carry a high risk of loss, including illiquidity and dilution. Do your own research.